Seeking to join consortia for target&biomarker validation and drug development projects

IMol PAS (https://imol.institute/) is a multidisciplinary research institute located in Warsaw, established in 2021. With scientific excellence as one of our core pillars, we conduct cutting-edge research combining molecular and cell biology, cancer biology, proteomics, chemical biology, and medicinal chemistry.

We are eager to join multinational, multidisciplinary consortia dedicated to addressing unmet medical needs and improving access to effective preventive and therapeutic interventions.

Our expertise includes:

• functional and mechanistic target validation;

• in vitro models for drug development, including tumor-on-chip, brain-on-chip, organoids, and iPSC-based models;

• compound screening in zebrafish;

• generation and integration of multi-omics data, particularly proteomics and chemoproteomics;

• cancer signaling and tumor–microenvironment interactions;

• RNA biology, RNA processing, and regulation of gene expression;

• mitochondrial biology and mitochondrial protein homeostasis;

• proteostasis and metabolic quality control;

• membrane biology and cellular mechanisms;

• molecular pharmacology and chemical biology.